Possibilities of chronic brain ischemia manifestations correction in outpatient practice
Cerebrovascular diseases (CVD) are one of the main causes of mortality and permanent disability in patients. Chronic brain ischemia (CBI) is a slowly progressive dysfunction of the brain with gradually increasing defects in its functioning, which is accompanied by energy deficiency. Early use of ene...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2021-01-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/5966 |
| Summary: | Cerebrovascular diseases (CVD) are one of the main causes of mortality and permanent disability in patients. Chronic brain ischemia (CBI) is a slowly progressive dysfunction of the brain with gradually increasing defects in its functioning, which is accompanied by energy deficiency. Early use of energy correctors, one of the representatives of which is ethylmethylhydroxypyridine succinate (EMHPS), is recommended to preserve the viability of nervous tissue in patients with CBI. A number of experimental, clinical, and randomized studies have shown that medicinal preparation (MP) containing EMHPS improve brain metabolism and blood supply, improve microcirculation, and reduce platelet aggregation. The main mechanisms of action are: antioxidant and membranotropic effects, the ability to reduce glutamate excitotoxicity, modulate the functioning of receptors and membrane-bound enzymes, restore neurotransmitter balance, and increase the energy status of the cell. The liberal MP EMHPS included in the standards of medical care for patients with stroke, angina pectoris, acute myocardial infarction. The presented data from the results of numerous studies and our own observation indicate that it is possible to correct cognitive, motor, coordination, and adaptive capabilities while taking EMGPS. Used for today the scheme of appointment of EMHPS in patients with CBI: starting from 500 mg once a day intravenously (i/v) in drip for 14 days, followed by a transition to oral reception (o/r) at a dose of 250 mg 3 times a day, a course of 60 days. |
|---|---|
| ISSN: | 2079-701X 2658-5790 |